Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)

20260 citationsJournal Article

Authors

Rong Ding · Kunming Medical University

Jin‐Feng Bai · Kunming Medical University

Z. Jin · Zhongda Hospital Southeast University

Yao Xiao · Central South University

Jian‐Jian Chen · Nanfang Hospital

Xiao‐Li Zhu · Soochow University

Yu‐Jing Xin ·

Abstract

The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Cholangiocarcinoma and Gallbladder Cancer Studies Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alimentary Pharmacology & Therapeutics

DOI: 10.1111/apt.70612

Field-Weighted Citation Impact: 0.00